A treatment program from Black Dog Institute is giving hope to people with Premenstrual Dysphoric Disorder (PMDD), according to the results of a new study published in Behaviour Research and Therapy.
PMDD is an often-misunderstood hormone-based disorder that causes debilitating physical, emotional and psychological symptoms in the 7–14 days before menstruation. The Black Dog Institute program is the first of its kind in Australia to target rumination and worry, the core components of a persistent cycle of intrusive thoughts known as repetitive negative thinking (RNT).
RNT is common in the general population, and previous studies have shown that engaging more frequently in RNT places people at higher risk of anxiety and depression. Recent research has also revealed a link between RNT and PMDD.
In particular, people with PMDD appear to be more likely to ruminate in response to distress or premenstrual symptoms than people without PMDD, and that rumination seems to have a greater negative effect on mood. While there isn’t as much research on worry, it’s actually a very similar type of thinking. We know that worry and rumination respond to similar treatment strategies, so our goal was to target both of them in this treatment program.”
Emily Upton, Lead Researcher and Clinical Psychologist, Black Dog Institute
Reducing symptom impacts for people with PMDD
Ms. Upton’s program was adapted from an existing Black Dog Institute intervention designed to help people manage RNT. Studies of this earlier intervention showed that specifically targeting RNT during treatment was highly effective in reducing depression and anxiety symptoms.
The new program is a brief, four-module digital intervention specifically adapted for people with PMDD that participants can complete at home with support from a clinical psychologist. It includes psychoeducation about PMDD, the link between PMDD and RNT, and evidence-based strategies to manage rumination and worry.
It also provides participants with menstrual cycle tracking tools to help them better understand the link between their symptoms and the specific period of the menstrual cycle, called the luteal phase, when PMDD symptoms occur.
“We were interested in whether the program helped reduce the severity of symptoms, but also in functional impact - so for example, how much the symptoms were interfering in people’s daily lives, and how many days per month were people unable to take part in their usual activities,” says Ms. Upton.
“We also looked at distress, impacts on mental wellbeing and frequency of suicidal thinking, all of which often go hand in hand with PMDD.”
An evaluation of the intervention showed a significant reduction in symptom severity and improvements in daily function. Feedback from participants also revealed that the program enhanced their understanding of PMDD and equipped them with practical skills that helped them manage RNT and other premenstrual symptoms.
“We saw significant improvements in almost all of the key outcomes of the study,” Ms. Upton says.
“Participants showed a large improvement immediately post-treatment, but even five weeks later - at least one menstrual cycle post-treatment - the effect size was even greater for many people.”
“It’s not your fault”: Validating the PMDD experience
In addition to its clinical benefits, the program was considered highly acceptable among participants, with the majority (96%) rating themselves as highly satisfied with the intervention and its outcomes. Many participants expressed a sense of feeling validated by taking part in research that acknowledged their experience of living with PMDD.
“People really valued having a treatment that was tailored for PMDD and that really recognized and validated their experiences as, yes, this is a real disorder and there are biological reasons for your symptoms,” Ms. Upton says.
“It’s not a personal failing and it’s not your fault.”
The study marks an exciting development in this still-emerging field in Australia. PMDD is a relatively new diagnosis, having only been included in the Diagnostic and Statistical Manual of Mental Disorders under its current name for the first time in 2013.
With research and clinical practice still catching up, many patients struggle to access treatment.
“Health professionals often don’t know how to recognize PMDD, the importance of assessing for it, how to diagnose it and what the treatment options are, which means it’s often missed,” Ms. Upton says.
“Our study is a hopefully meaningful step towards addressing the gap in available psychological treatments for PMDD.”
The study screening and evaluation questionnaires also included a series of open-ended feedback questions that provide important signposts towards future research opportunities. In particular, participants reflected on their need for broader symptom support and help managing the impact of those symptoms on work and relationships.
“We got so much feedback from people saying yes, rumination and worry are really important, but we also need help with things like suicidal thinking, irritability, concentration difficulties and fatigue and support to minimize the impact of PMDD symptoms on relationships, work and self-care,” Ms. Upton says.
With support from a James N. Kirby Foundation grant, Ms. Upton is now working to expand the program to address a broader range of PMDD symptoms.